Semaglutide

1. Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes mellitus (T2D) and chronic weight management [1][15]. It is a synthetic analog of human GLP-1 with 94% structural homology to the native incretin hormone, incorporating three key modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8, an arginine substitution at position 34, and a C18 fatty diacid chain conjugated to lysine at position 26 via a linker [15].

The C18 fatty diacid modification is central to semaglutide's pharmacokinetic profile. This lipophilic side chain enables strong non-covalent binding to serum albumin, which shields the molecule from renal clearance and enzymatic degradation, producing a plasma half-life of approximately 165 hours (~7 days) [15]. This extended half-life permits once-weekly subcutaneous administration, a meaningful advantage over earlier GLP-1 receptor agonists requiring daily or twice-daily dosing.

Semaglutide has received regulatory approval from the U.S. Food and Drug Administration (FDA) under three brand names: Ozempic (subcutaneous injection for T2D, approved December 2017), Rybelsus (oral tablet for T2D, approved September 2019), and Wegovy (subcutaneous injection for chronic weight management, approved June 2021) [1][4][11]. It has also been approved by the European Medicines Agency (EMA) and regulatory bodies in numerous other jurisdictions.

Molecular Weight

4113.58 g/mol

Sequence

Modified GLP-1(7-37) analog with Aib8, Arg34, C18 fatty diacid at Lys26

Half-life

~7 days (subcutaneous)

Routes Studied

Subcutaneous injection (weekly, up to 7.2 mg), oral tablet (daily, up to 25 mg)

FDA Status

Approved: Ozempic (T2D, 2017), Wegovy (obesity, 2021; MASH, 2025), Wegovy HD (7.2 mg, 2026), Rybelsus (oral, T2D, 2019; CV risk, 2025), Oral Wegovy (25 mg, weight, 2025)

WADA Status

Not prohibited

2. Mechanism of Action

Semaglutide exerts its physiological effects through selective activation of the GLP-1 receptor, a G-protein-coupled receptor expressed in the pancreas, gastrointestinal tract, central nervous system, cardiovascular system, and kidneys [15].

Pancreatic effects. In pancreatic beta cells, GLP-1 receptor activation stimulates glucose-dependent insulin secretion through increased intracellular cyclic AMP (cAMP) signaling [15]. Because insulin release is potentiated only in the presence of elevated blood glucose, the risk of hypoglycemia is low when semaglutide is used as monotherapy. Semaglutide also suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, further contributing to glycemic control [2].

Central nervous system effects. Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in hypothalamic and hindbrain regions involved in appetite regulation, including the arcuate nucleus and the nucleus of the solitary tract [15]. This central action is believed to mediate the reductions in hunger and food intake observed in clinical trials. Neuroimaging studies suggest that semaglutide may alter food reward processing and reduce cravings for high-fat, energy-dense foods.

Gastrointestinal effects. Semaglutide delays gastric emptying, which contributes to reduced postprandial glucose excursions and may enhance satiety [15]. This effect appears most pronounced during the initial weeks of treatment and may attenuate partially with continued use.

Resistance to enzymatic degradation. Native GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), with a circulating half-life of approximately 2 minutes. The Aib8 substitution in semaglutide confers resistance to DPP-4 cleavage, while albumin binding via the C18 fatty diacid further protects against neutral endopeptidase degradation and renal elimination [15].

Cardiovascular and renal pathways. GLP-1 receptor activation has been associated with anti-inflammatory effects on vascular endothelium, reduction in systolic blood pressure, and improvements in lipid profiles [1][9]. The mechanisms underlying the observed cardiovascular and renal benefits of semaglutide are an area of active investigation and may involve both direct receptor-mediated effects and indirect benefits from improvements in metabolic parameters.

3. Pharmacokinetics

The pharmacokinetic profile of semaglutide is shaped by its C18 fatty diacid side chain, which confers strong albumin binding and protects the molecule from proteolytic degradation and renal filtration [15][17].

Absorption

Subcutaneous administration. After subcutaneous injection, semaglutide is absorbed slowly from the injection depot, reaching peak plasma concentration (Tmax) at approximately 1 to 3 days post-dose [17]. Absolute bioavailability following subcutaneous administration is approximately 89%, reflecting efficient absorption from the subcutaneous tissue into the systemic circulation. Absorption is comparable across injection sites (abdomen, thigh, upper arm) [17].

Oral administration. Oral semaglutide is co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), which transiently increases gastric pH locally and promotes transcellular absorption across the gastric epithelium [18]. Oral bioavailability is approximately 0.4 to 1%, reflecting the inherent challenge of oral peptide delivery. Tmax for oral semaglutide occurs at approximately 1 hour post-dose in the fasting state [18]. Absorption is markedly reduced by food intake (up to 40% reduction when taken with food vs fasting), fluid volume beyond 120 mL, and co-administration with other oral medications during the absorption window. These constraints necessitate the strict fasting protocol for oral dosing.

Distribution

Semaglutide has a small apparent volume of distribution (Vd) of approximately 12.5 L following subcutaneous administration, consistent with a molecule that remains predominantly in the vascular compartment due to extensive albumin binding [17]. Plasma protein binding exceeds 99%, with albumin being the primary binding partner. This high degree of albumin binding is the principal mechanism responsible for the extended plasma half-life and also limits tissue distribution, largely confining semaglutide to the plasma and interstitial fluid compartments.

Metabolism and Elimination

Semaglutide is eliminated through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, analogous to the catabolism of endogenous peptides and fatty acids [17]. Importantly, semaglutide is not a substrate for cytochrome P450 (CYP) enzymes, and CYP-mediated metabolism does not contribute meaningfully to its clearance. This characteristic minimizes the potential for pharmacokinetic drug-drug interactions with CYP substrates, inhibitors, or inducers.

The terminal half-life is approximately 165 hours (~7 days) for both subcutaneous and oral formulations, enabling once-weekly dosing for the subcutaneous route [15][17]. Steady-state plasma concentrations are achieved after approximately 4 to 5 weeks of once-weekly dosing. Elimination occurs primarily via the urine (approximately 3% of the dose is excreted as intact semaglutide) and feces (approximately 53% of the oral dose as metabolites), with the remainder eliminated through expired air as CO2 from beta-oxidation of the fatty acid moiety [17].

Pharmacokinetics in Special Populations

Renal impairment. Population pharmacokinetic analyses from clinical trials indicate that mild, moderate, or severe renal impairment (including end-stage renal disease) does not affect semaglutide exposure to a clinically relevant degree [17]. No dose adjustment is required in patients with renal impairment. The FLOW trial confirmed safety and efficacy in patients with eGFR as low as 25 mL/min/1.73 m2 [10].

Hepatic impairment. Dedicated studies in patients with mild, moderate, and severe hepatic impairment (Child-Pugh A, B, and C) demonstrated no clinically significant effect on semaglutide pharmacokinetics [17]. No dose adjustment is required.

Obesity. Body weight does not have a clinically meaningful effect on semaglutide exposure at therapeutic doses. Population PK analyses across the STEP trials, which included participants with body weights ranging from approximately 60 kg to over 200 kg, confirmed adequate exposure across the weight spectrum without need for weight-based dose adjustment [17].

Age, sex, and race. Age (18-92 years), sex, and race/ethnicity do not significantly affect semaglutide pharmacokinetics based on population analyses across clinical programs [17].

4. Dose-Response Relationships

Glycemic Control: SUSTAIN Dose-Response

The SUSTAIN trial program established a clear dose-response relationship for HbA1c reduction with subcutaneous semaglutide. In SUSTAIN-1, monotherapy with semaglutide 0.5 mg weekly reduced HbA1c by 1.45% from baseline, while the 1.0 mg dose produced a reduction of 1.55% [2]. Across the SUSTAIN program, the incremental benefit of 1.0 mg over 0.5 mg was modest for glycemic control (approximately 0.1-0.3% additional HbA1c reduction) but more substantial for body weight reduction (approximately 1-2 kg additional weight loss) [2][3].

For oral semaglutide in the PIONEER program, HbA1c reductions showed a dose-dependent pattern: 3 mg daily produced approximately 0.6-0.9% reductions, 7 mg produced approximately 1.0-1.3% reductions, and 14 mg produced approximately 1.3-1.5% reductions from baseline, depending on the comparator trial and baseline HbA1c [11].

Weight Loss: STEP Dose-Response

The dose-response for weight loss across the STEP trials reveals meaningful differences between the 1.0 mg diabetes dose and the 2.4 mg obesity dose:

Semaglutide 1.0 mg weekly typically produces 5-7% mean body weight loss in patients with type 2 diabetes, as observed in the SUSTAIN program [2][3].

Semaglutide 2.4 mg weekly produces substantially greater weight loss: 14.9% in STEP 1 (obesity without diabetes), 9.6% in STEP 2 (obesity with T2D), and 15.2% over two years in STEP 5 [4][5][8]. In STEP 2, which included a 1.0 mg comparator arm, semaglutide 1.0 mg produced 7.0% weight loss compared to 9.6% with 2.4 mg, confirming a dose-response in the same patient population [5].

Dose-Escalation Rationale

The 16-week dose-escalation protocol used in the STEP program (0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg, each step lasting 4 weeks) was designed primarily to improve gastrointestinal tolerability [4]. Rapid escalation to the full 2.4 mg dose significantly increases the incidence and severity of nausea, vomiting, and diarrhea. The gradual titration allows tachyphylaxis of the emetic response to develop, resulting in substantially lower rates of discontinuation due to gastrointestinal adverse events compared to approaches without dose escalation.

Higher Doses: Emerging Evidence

The STEP UP trial (2025) provided definitive evidence for higher-dose semaglutide. In this Phase 3b randomized, double-blind trial of approximately 1,407 adults with obesity without diabetes, semaglutide 7.2 mg once weekly achieved a mean weight loss of 20.7% over 72 weeks, compared to 13.7% with semaglutide 2.4 mg [26]. Approximately one in three participants in the 7.2 mg group achieved 25% or greater weight loss. In the STEP UP T2D trial, semaglutide 7.2 mg produced 14.1% mean weight loss in participants with obesity and type 2 diabetes, confirming the dose-response relationship in this harder-to-treat population.

Based on these results, the FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, under an accelerated review. The approval was granted just 54 days after filing, reflecting the designation as a national health priority. Wegovy HD is expected to launch in the US in April 2026 [26].

The gastrointestinal tolerability profile at 7.2 mg was broadly consistent with the known safety profile of semaglutide, though a gradual dose-escalation protocol was employed. The favorable risk-benefit profile at this higher dose narrows the weight-loss gap between semaglutide and dual-agonist agents such as tirzepatide.

5. Comparative Effectiveness

Semaglutide vs Liraglutide

The most direct head-to-head comparison for weight management comes from STEP 8, a 68-week randomized trial comparing semaglutide 2.4 mg weekly with liraglutide 3.0 mg daily (the approved anti-obesity dose) in 338 adults with overweight or obesity without diabetes [16]. Results were unequivocal:

• Mean weight loss: semaglutide 15.8% vs liraglutide 6.4% (estimated treatment difference: -9.4 percentage points; 95% CI, -12.0 to -6.8; P value 0.001)
• Proportion achieving 10% or greater weight loss: semaglutide 70.9% vs liraglutide 25.6%
• Proportion achieving 20% or greater weight loss: semaglutide 38.5% vs liraglutide 6.0%
• Gastrointestinal adverse events were comparable between groups (semaglutide 84.1% vs liraglutide 82.7%), though the types differed slightly in distribution

For diabetes management, SUSTAIN-10 compared semaglutide 1.0 mg weekly with liraglutide 1.2 mg daily (the lower diabetes dose, not the weight management dose). Semaglutide demonstrated superiority in HbA1c reduction (-1.7% vs -1.0%) and body weight reduction (-5.8 kg vs -1.9 kg) over 30 weeks [12].

The NNT (number needed to treat) for achieving 10% or greater weight loss with semaglutide 2.4 mg vs liraglutide 3.0 mg in STEP 8 was approximately 3 (1 / [0.709 - 0.256] = 2.2), indicating that for every 2-3 patients switched from liraglutide to semaglutide, one additional patient would achieve clinically meaningful 10% or greater weight loss [16].

Semaglutide vs Tirzepatide

The SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, provided the first head-to-head randomized comparison of tirzepatide and semaglutide for weight management [27]. In this Phase 3b, open-label trial, 751 adults with obesity but without type 2 diabetes were randomly assigned 1:1 to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) once weekly for 72 weeks.

Results demonstrated tirzepatide's superiority:

• Mean weight loss at 72 weeks: tirzepatide 20.2% vs semaglutide 13.7% (estimated treatment difference: -6.5 percentage points; P < 0.001)
• Mean waist circumference reduction: tirzepatide 18.4 cm vs semaglutide 13.0 cm (P < 0.001)
• Proportion achieving 30% or greater weight loss: tirzepatide 19.7% vs semaglutide 6.9%
• GI adverse events causing discontinuation: tirzepatide 2.7% vs semaglutide 5.6%

These results confirm and extend prior indirect cross-trial comparisons. Tirzepatide's dual GIP/GLP-1 receptor agonism likely confers additional weight loss through complementary metabolic mechanisms. However, the open-label design of SURMOUNT-5 is a limitation that should be considered when interpreting these findings.

It should be noted that the SURMOUNT-5 trial compared semaglutide at its then-approved maximum dose of 2.4 mg. With the FDA approval of Wegovy HD (semaglutide 7.2 mg) in March 2026, the STEP UP trial demonstrated 20.7% mean weight loss at the higher dose [26], which is comparable to the 20.2% achieved by tirzepatide in SURMOUNT-5. Head-to-head comparisons at these updated dose levels have not yet been conducted.

For glycemic control in type 2 diabetes, the SURPASS-2 trial compared tirzepatide (5 mg, 10 mg, and 15 mg weekly) with semaglutide 1.0 mg weekly. All three tirzepatide doses demonstrated superior HbA1c reductions compared to semaglutide 1.0 mg, with the 15 mg dose producing a -2.30% reduction vs -1.86% with semaglutide.

Semaglutide vs Lifestyle Intervention Alone

Across the STEP program, the lifestyle intervention (counseling on a 500 kcal/day deficit diet and 150 minutes/week of physical activity) served as the background therapy for all groups, including placebo. The placebo plus lifestyle arms achieved 2.4% (STEP 1), 3.4% (STEP 2), and 5.7% (STEP 3, intensive behavioral therapy) weight loss over 68 weeks [4][5][6]. The incremental benefit of adding semaglutide 2.4 mg to lifestyle intervention was therefore approximately 10-12.5 percentage points of additional weight loss, representing a roughly 3- to 6-fold amplification of the lifestyle effect alone.

Semaglutide vs Bariatric Surgery

Direct randomized comparison of semaglutide with bariatric surgery has not been conducted. However, indirect comparison with landmark surgical trials provides context:

• STEP 1 (semaglutide 2.4 mg): 14.9% mean weight loss at 68 weeks [4]
• Roux-en-Y gastric bypass (STAMPEDE trial): approximately 25-30% weight loss at 1 year
• Sleeve gastrectomy: approximately 20-25% weight loss at 1 year

Semaglutide produces less absolute weight loss than bariatric surgery but offers a non-surgical alternative with a different risk-benefit profile. Key distinctions include: semaglutide requires ongoing treatment to maintain weight loss (STEP 4 demonstrated regain upon discontinuation) [7], whereas bariatric surgery effects are generally more durable; surgical approaches carry perioperative risks (approximately 0.1-0.5% mortality for RYGB) but do not require indefinite pharmacotherapy; and semaglutide may be combined with surgery for patients with inadequate surgical response.

6. Researched Applications

Type 2 Diabetes (Strong Evidence)

The SUSTAIN clinical trial program (SUSTAIN 1 through SUSTAIN 10) established semaglutide as an effective glucose-lowering therapy across the spectrum of type 2 diabetes management [2][3][12]. In SUSTAIN-1, semaglutide monotherapy at doses of 0.5 mg and 1.0 mg weekly reduced HbA1c by 1.45% and 1.55% respectively compared to placebo over 30 weeks [2]. Head-to-head trials demonstrated superiority over sitagliptin (SUSTAIN-2), exenatide extended-release (SUSTAIN-3), insulin glargine (SUSTAIN-4), dulaglutide (SUSTAIN-7), and liraglutide (SUSTAIN-10) in HbA1c reduction [3][12].

Oral semaglutide (Rybelsus) was evaluated in the PIONEER trial program. PIONEER-1 demonstrated that oral semaglutide 14 mg daily reduced HbA1c by 1.5% from baseline compared to 0.02% with placebo over 26 weeks [11]. The oral formulation uses a co-formulated absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to facilitate transcellular absorption across gastric epithelium.

Weight Management (Strong Evidence)

The STEP clinical trial program evaluated semaglutide 2.4 mg weekly for chronic weight management. In STEP 1, the pivotal trial, adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) achieved a mean weight loss of 14.9% from baseline over 68 weeks, compared to 2.4% with placebo [4]. Approximately one-third of participants lost 20% or more of their body weight. STEP 2 demonstrated a mean weight loss of 9.6% in patients with coexisting type 2 diabetes, a population in which weight loss is typically more difficult to achieve [5]. STEP 3 showed that combining semaglutide with intensive behavioral therapy produced 16.0% mean weight loss [6], while STEP 4 demonstrated that discontinuation of semaglutide led to regain of approximately two-thirds of prior weight loss, underscoring the need for continued treatment [7]. STEP 5 confirmed durability of weight loss (15.2%) over a two-year treatment period [8].

Cardiovascular Protection (Strong Evidence)

SUSTAIN-6 provided the initial signal that semaglutide may reduce cardiovascular risk. In 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared to placebo (HR 0.74; 95% CI, 0.58-0.95) [1].

The SELECT trial subsequently provided definitive evidence of cardiovascular benefit independent of diabetes. In 17,604 adults aged 45 years or older with established cardiovascular disease and BMI of 27 or greater, but without diabetes, semaglutide 2.4 mg weekly reduced MACE by 20% compared to placebo over a mean follow-up of 39.8 months (HR 0.80; 95% CI, 0.72-0.90) [9]. This was the first trial to demonstrate cardiovascular risk reduction with an anti-obesity medication in a population without diabetes.

The PIONEER-6 trial assessed cardiovascular safety of oral semaglutide and demonstrated non-inferiority to placebo with a point estimate suggesting potential benefit (HR 0.79; 95% CI, 0.57-1.11) [13]. The subsequent SOUL trial (2025) definitively confirmed cardiovascular benefit for oral semaglutide: in 9,650 patients with type 2 diabetes at high cardiovascular risk, oral semaglutide 14 mg daily reduced MACE by 14% compared to placebo (HR 0.86) over a mean follow-up of 47.5 months, leading to FDA label expansion for Rybelsus to include cardiovascular risk reduction [25].

Kidney Protection

The FLOW trial evaluated semaglutide 1.0 mg weekly in 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 25-75 mL/min/1.73 m2 with albuminuria). Semaglutide reduced the primary composite endpoint of kidney disease progression (sustained 50% or greater decline in eGFR, kidney failure, kidney-related death, or cardiovascular death) by 24% compared to placebo (HR 0.76; 95% CI, 0.66-0.88) [10]. The trial was stopped early for efficacy, making semaglutide the first GLP-1 receptor agonist to demonstrate a primary kidney outcome benefit in a dedicated renal trial.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) (Strong Evidence)

The ESSENCE trial, published in the New England Journal of Medicine in April 2025, evaluated semaglutide 2.4 mg weekly in patients with biopsy-confirmed MASH and moderate-to-advanced liver fibrosis (stages F2-F3) [23]. At 72 weeks, semaglutide met both co-primary endpoints:

• Resolution of steatohepatitis without worsening fibrosis: 62.9% vs 34.3% with placebo (estimated difference 28.7 percentage points; 95% CI, 21.1 to 36.2; P < 0.001)
• Improvement in liver fibrosis without worsening steatohepatitis: 36.8% vs 22.4% with placebo (estimated difference 14.4 percentage points; 95% CI, 7.5 to 21.3; P < 0.001)

Secondary endpoints demonstrated improvements in non-invasive fibrosis markers, liver stiffness by elastography, aminotransferases, and composite risk scores. Metabolic benefits included approximately 10% body weight reduction and improvements in glycemia, blood pressure, and lipid parameters.

On August 15, 2025, the FDA granted accelerated approval to Wegovy (semaglutide 2.4 mg injection) for the treatment of adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis (stages F2-F3), making semaglutide the first GLP-1 receptor agonist approved for this indication [30].

Heart Failure with Preserved Ejection Fraction (Strong Evidence)

The STEP-HFpEF trial evaluated semaglutide 2.4 mg weekly in 529 patients with heart failure with preserved ejection fraction (HFpEF) and a BMI of 30 or higher over 52 weeks [22]. Semaglutide demonstrated significant improvements in both dual primary endpoints:

• KCCQ clinical summary score (symptoms and physical limitations): +16.6 points vs +8.7 points with placebo (estimated treatment difference 7.8 points; 95% CI, 4.8 to 10.9; P < 0.001)
• Body weight reduction: -13.3% vs -1.8% with placebo (P < 0.001)

Key secondary outcomes included improvement in 6-minute walk distance (+21.5 m vs +1.2 m) and reduced C-reactive protein levels. The STEP-HFpEF DM trial extended these findings to patients with HFpEF and coexisting type 2 diabetes, demonstrating similar benefits with a marked reduction in heart failure events (HR 0.40). A pooled analysis of semaglutide trials in HFpEF published in 2024 confirmed that semaglutide reduced the risk of the combined endpoint of cardiovascular death or worsening heart failure events [22].

Oral Semaglutide for Weight Management (Strong Evidence)

The OASIS 4 trial, published in the New England Journal of Medicine in September 2025, evaluated oral semaglutide 25 mg daily in adults with overweight or obesity without diabetes over 64 weeks [24]. Results demonstrated:

• Mean weight loss (intention-to-treat): -13.6% vs -2.2% with placebo (estimated difference -11.4 percentage points)
• Mean weight loss (treatment-adherent): -16.6% vs -2.7% with placebo
• Proportion achieving 20% or greater weight loss (adherent): approximately one-third vs under 3% with placebo

The FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025, making it the first oral GLP-1 receptor agonist approved for chronic weight management. The oral formulation uses an enhanced SNAC co-formulation to achieve substantially higher bioavailability than the existing Rybelsus 14 mg tablet [24].

Alcohol Use Disorder (Emerging Evidence)

A Phase 2 randomized clinical trial published in JAMA Psychiatry in February 2025 evaluated low-dose semaglutide in adults with alcohol use disorder (AUD) [28]. Over 9 weeks of treatment, semaglutide reduced alcohol consumption in a posttreatment laboratory self-administration task with medium to large effect sizes. Semaglutide significantly reduced weekly alcohol craving relative to placebo and also led to greater reductions in cigarettes per day in a subgroup of participants with concurrent cigarette use. Phase 3 trials evaluating semaglutide for AUD are underway [28].

Alzheimer's Disease (Negative Result)

The EVOKE and EVOKE+ Phase 3 trials evaluated oral semaglutide in 3,808 adults aged 55-85 with early-stage symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia with confirmed amyloid positivity). Topline results announced in November 2025 showed that both trials failed to meet their primary endpoint of slowing cognitive and functional decline as measured by the CDR-SB (Clinical Dementia Rating - Sum of Boxes) scale [29]. While semaglutide reduced neuroinflammation biomarkers by up to 10%, these improvements did not translate into clinical benefit. Based on these results, Novo Nordisk discontinued the one-year extension periods of both trials [29].

Other Investigated Uses

Additional indications under investigation include obstructive sleep apnea, peripheral artery disease, and polycystic kidney disease. Retrospective analyses suggest GLP-1 receptor agonists may reduce the incidence and severity of obstructive sleep apnea, likely mediated through weight loss, though dedicated randomized trials of semaglutide for this indication are limited.

7. Clinical Evidence Summary

8. Dosing in Research

In clinical trials, semaglutide has been administered via two routes: subcutaneous injection (once weekly) and oral tablet (once daily). Both formulations follow a gradual dose-escalation protocol to mitigate gastrointestinal side effects.

For subcutaneous semaglutide in type 2 diabetes (SUSTAIN program), the starting dose was 0.25 mg weekly for 4 weeks, followed by escalation to 0.5 mg weekly, with the option to increase to 1.0 mg weekly based on glycemic response [2]. For chronic weight management (STEP program), the dose was escalated from 0.25 mg weekly over 16 weeks to a target maintenance dose of 2.4 mg weekly [4].

Oral semaglutide (PIONEER program) was initiated at 3 mg daily for 30 days, increased to 7 mg daily for 30 days, and then to 14 mg daily [11]. The oral tablet must be taken in the fasting state with no more than 120 mL (4 oz) of plain water, and patients must wait at least 30 minutes before eating, drinking, or taking other oral medications, as food and fluid volume reduce absorption.

9. Safety and Side Effects

The safety profile of semaglutide has been characterized in clinical trials involving over 40,000 participants across the SUSTAIN, STEP, PIONEER, SELECT, and FLOW programs [1][4][9][10][11].

Gastrointestinal effects. The most frequently reported adverse events are gastrointestinal in nature. Pooled analysis across the STEP program at the 2.4 mg dose yields the following incidence rates compared to placebo [4][21]:

• Nausea: 42-44% vs 15-16% (placebo); typically peaks during weeks 1-8 of dose escalation
• Diarrhea: 29-31% vs 15-16% (placebo)
• Vomiting: 24-25% vs 6-7% (placebo)
• Constipation: 23-24% vs 10-11% (placebo)
• Abdominal pain: 10-11% vs 6-7% (placebo)
• Dyspepsia: 8-9% vs 3-4% (placebo)

These effects are generally mild to moderate in severity (grade 1-2), occur most commonly during dose escalation, and tend to diminish with continued treatment as tachyphylaxis develops. Gastrointestinal side effects were the most common reason for treatment discontinuation in the STEP trials, occurring in approximately 7% of semaglutide-treated participants versus 3% of placebo-treated participants [4]. The dose-escalation protocol reduces but does not eliminate these events.

Pancreatitis. Acute pancreatitis has been reported in clinical trials at low rates. In SUSTAIN-6, pancreatitis occurred in 0.1% of semaglutide-treated patients versus 0.5% of placebo-treated patients [1]. While the overall incidence is low, semaglutide is contraindicated in patients with a personal history of pancreatitis in some jurisdictions, and patients should be monitored for signs and symptoms.

Gallbladder disorders. Cholelithiasis and cholecystitis have been observed at higher rates with semaglutide than with placebo, particularly at the 2.4 mg dose used for weight management. In STEP 1, gallbladder-related events occurred in 2.6% of semaglutide-treated participants versus 1.2% of placebo-treated participants [4]. In the SELECT trial, cholelithiasis occurred in 2.8% vs 2.3% of participants (semaglutide vs placebo) and cholecystitis in 1.0% vs 0.7% [9][21].

The mechanism of GLP-1 agonist-associated cholelithiasis is multifactorial. Rapid weight loss increases hepatic cholesterol secretion into bile, supersaturating bile with cholesterol and promoting nucleation of cholesterol crystals. Additionally, GLP-1 receptor agonists reduce gallbladder motility by inhibiting cholecystokinin-mediated contraction, leading to biliary stasis. The combination of cholesterol-supersaturated bile and impaired gallbladder emptying creates favorable conditions for gallstone formation. Risk is greatest during the period of active weight loss and in patients with pre-existing biliary sludge or a history of gallstones [21].

Thyroid C-cell tumors. In two-year rodent carcinogenicity studies, semaglutide and other GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) in both rats and mice at all clinically relevant doses tested [15][20]. In rats, C-cell tumors were observed at exposures as low as 0.36 times the maximum recommended human dose based on AUC. The mechanism involves direct GLP-1 receptor activation on rodent thyroid C-cells, stimulating calcitonin release and promoting C-cell proliferation in a receptor-dependent manner [20].

The human relevance of this finding is considered low for several reasons: (1) GLP-1 receptor expression on human thyroid C-cells is approximately 10- to 100-fold lower than in rodents; (2) GLP-1 receptor agonists do not increase serum calcitonin levels in humans, even at supratherapeutic exposures; (3) large epidemiological analyses of GLP-1 receptor agonist use (spanning over 15 years of market experience with exenatide and liraglutide) have not identified a signal for increased MTC incidence; and (4) the density of C-cells in the human thyroid is substantially lower than in rodents [20][21].

Nevertheless, semaglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled about potential symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). Routine serum calcitonin monitoring is not recommended for clinical decision-making, as it has poor predictive value in this context [21].

Diabetic retinopathy. SUSTAIN-6 observed a higher rate of diabetic retinopathy complications in semaglutide-treated patients (3.0%) compared to placebo (1.8%), potentially related to rapid improvement in glycemic control in patients with pre-existing retinopathy [1].

Suicidal ideation and behavior. Following post-marketing reports, the FDA initiated a formal investigation in 2023 into a potential association between GLP-1 receptor agonists (including semaglutide) and suicidal thoughts or actions [19]. Preliminary analysis of data from the FAERS database and clinical trial programs was reported in early 2024. The FDA's evaluation found no causal link between semaglutide and suicidality based on available clinical trial data. In pooled analyses across the STEP and SELECT programs, the incidence of suicidal ideation was numerically similar in semaglutide and placebo groups. The EMA conducted a parallel review and reached a similar conclusion. However, the FDA stated that its investigation remains ongoing and that further evaluation through post-marketing surveillance and real-world evidence studies continues. Clinicians are advised to monitor patients for changes in mood or behavior, particularly those with a pre-existing history of psychiatric disorders [19][21].

Drug interaction profile. Because semaglutide is metabolized through proteolytic degradation and fatty acid beta-oxidation rather than CYP-mediated pathways, it has a favorable drug interaction profile [17]. No clinically significant pharmacokinetic interactions have been demonstrated with commonly co-prescribed medications, including metformin, warfarin, atorvastatin, digoxin, oral contraceptives (ethinylestradiol/levonorgestrel), or furosemide. However, semaglutide's effect on gastric emptying delay may affect the absorption rate (but generally not the extent) of concomitant oral medications. For drugs with a narrow therapeutic index that require rapid absorption for efficacy, monitoring may be warranted during semaglutide initiation and dose escalation. The oral semaglutide formulation requires particular attention to administration timing, as the SNAC co-formulation may transiently alter gastric pH, and concomitant oral medications should not be taken within 30 minutes of the oral semaglutide dose [17][18].

Other considerations. Heart rate increases of 1-4 beats per minute have been observed with semaglutide treatment across clinical programs, likely mediated by direct sinoatrial node GLP-1 receptor activation and sympathetic nervous system modulation. This effect does not appear to be associated with adverse cardiovascular outcomes, as evidenced by the cardiovascular benefit demonstrated in SUSTAIN-6 and SELECT [1][9]. Injection site reactions are generally mild and infrequent (occurring in 0.2-1.0% of participants). The risk of hypoglycemia is low with semaglutide monotherapy (0.1-0.4% for severe hypoglycemia) but increases when used in combination with sulfonylureas or insulin, necessitating dose reduction of the concomitant secretagogue [21].

10. Regulatory Status

Semaglutide has received regulatory approval in numerous jurisdictions worldwide:

United States (FDA). Ozempic (semaglutide injection 0.5 mg, 1.0 mg, and 2.0 mg) was approved in December 2017 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. Rybelsus (oral semaglutide 7 mg and 14 mg tablets) was approved in September 2019 for the same indication, representing the first oral GLP-1 receptor agonist [11]. In October 2025, the FDA expanded the Rybelsus label to include reduction of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, based on the SOUL trial, making it the first oral GLP-1 receptor agonist with a cardiovascular risk reduction indication [25]. Wegovy (semaglutide injection 2.4 mg) was approved in June 2021 for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity [4]. In March 2024, following the SELECT trial results, the FDA approved a cardiovascular risk reduction indication for Wegovy in adults with established cardiovascular disease and overweight or obesity [9]. In August 2025, the FDA granted accelerated approval for Wegovy to treat adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis (stages F2-F3), based on the ESSENCE trial [23][30]. The oral Wegovy tablet (semaglutide 25 mg daily) was approved on December 22, 2025, for chronic weight management, becoming the first oral GLP-1 receptor agonist approved for weight loss [24]. On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg injection), the highest-dose formulation, for chronic weight management, based on the STEP UP trial demonstrating 20.7% mean weight loss [26].

European Union (EMA). Ozempic received marketing authorization in February 2018. Rybelsus was approved in April 2020. Wegovy was approved in January 2022.

Oral formulation. The development of oral semaglutide represented a significant pharmaceutical achievement, as peptides are typically degraded in the gastrointestinal tract. The co-formulation with the absorption enhancer SNAC enables sufficient bioavailability for therapeutic effect, though oral bioavailability remains approximately 1% [11][15]. The approval of the oral Wegovy 25 mg tablet in December 2025 marked a further advance, extending the oral semaglutide platform from diabetes management to chronic weight management and achieving weight loss comparable to the injectable 2.4 mg formulation [24].

11. Related Peptides

See also: Tirzepatide, CJC-1295

12. References

1. [1] Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
2. [2] Sorli C, Harashima SI, Tsoukas GM, et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. DOI PubMed
3. [3] Pratley RE, Aroda VR, Lingvay I, et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology. DOI PubMed
4. [4] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. DOI PubMed
5. [5] Davies M, Faerch L, Jeppesen OK, et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. DOI PubMed
6. [6] Wadden TA, Bailey TS, Billings LK, et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. DOI PubMed
7. [7] Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. DOI PubMed
8. [8] Garvey WT, Batterham RL, Bhatt DL, et al. (2022). Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine. DOI PubMed
9. [9] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. DOI PubMed
10. [10] Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
11. [11] Aroda VR, Rosenstock J, Terauchi Y, et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. DOI PubMed
12. [12] Capehorn MS, Catarig AM, Furberg JK, et al. (2019). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic medications in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & Metabolism. DOI PubMed
13. [13] Husain M, Birkenfeld AL, Donsmark M, et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
14. [14] Davies MJ, Bergenstal R, Bode B, et al. (2015). Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. DOI PubMed
15. [15] Knudsen LB, Lau J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. DOI PubMed
16. [16] Rubino DM, Greenway FL, Khalid U, et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. DOI PubMed
17. [17] Jensen AB, Renber S, Garvey WT, et al. (2021). Pharmacokinetics and Pharmacodynamics of Subcutaneous Semaglutide. Clinical Pharmacokinetics. DOI PubMed
18. [18] Granhall C, Donsmark M, Blicher TM, et al. (2019). Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. DOI PubMed
19. [19] FDA. (2024). FDA Drug Safety Communication: FDA reports preliminary findings from its evaluation of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. FDA Safety Communications.
20. [20] Bjerre Knudsen L, Madsen LW, Andersen S, et al. (2010). Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. DOI PubMed
21. [21] Smits MM, Van Raalte DH. (2021). Safety of Semaglutide. Frontiers in Endocrinology. DOI PubMed
22. [22] Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. DOI PubMed
23. [23] Newsome PN, Sanyal AJ, Engebretsen KA, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. New England Journal of Medicine. DOI PubMed
24. [24] Knop FK, Aroda VR, do Vale RD, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. DOI PubMed
25. [25] Novo Nordisk. (2025). SOUL trial: Oral semaglutide 14 mg demonstrates superior reduction in cardiovascular events. ACC 2025 / Novo Nordisk Press Release.
26. [26] Jastreboff AM, Aronne LJ, Engberg S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology. DOI
27. [27] Aronne LJ, Sattar N, Horn DB, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. DOI PubMed
28. [28] Hendershot CS, Engel KG, Engel CC, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. DOI PubMed
29. [29] Novo Nordisk. (2025). EVOKE and EVOKE+ topline results: Semaglutide in early-stage symptomatic Alzheimer's disease. Novo Nordisk Press Release.
30. [30] FDA. (2025). FDA Approves Treatment for Serious Liver Disease Known as MASH. FDA News Release.